Workflow
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Globenewswire·2025-10-01 11:17

Awarded contract base period of US3.6milliontofundvaccinemanufacturingwithadditionaloptionperiodstoadvancedevelopmentthroughPhase1trialsSubmitteduptoUS3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US97 million in additional U.S. government funding proposals HALIFAX, Nova Scotia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, and its partner Vitalex Biosciences (“Vitalex”) today announc ...